158 related articles for article (PubMed ID: 38676801)
1. Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.
Yáñez-Bartolomé M; Serra-Camprubí Q; Arenas EJ; Escorihuela M; Castet F; Fabregat-Franco C; Querol J; Arribas J; Peiró S; Macarulla T; Tian TV
Methods Mol Biol; 2024; 2806():139-151. PubMed ID: 38676801
[TBL] [Abstract][Full Text] [Related]
2. Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model.
Vaeteewoottacharn K; Pairojkul C; Kariya R; Muisuk K; Imtawil K; Chamgramol Y; Bhudhisawasdi V; Khuntikeo N; Pugkhem A; Saeseow OT; Silsirivanit A; Wongkham C; Wongkham S; Okada S
Cells; 2019 May; 8(5):. PubMed ID: 31126020
[TBL] [Abstract][Full Text] [Related]
3. Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
Serra-Camprubí Q; Verdaguer H; Oliveros W; Lupión-Garcia N; Llop-Guevara A; Molina C; Vila-Casadesús M; Turpin A; Neuzillet C; Frigola J; Querol J; Yáñez-Bartolomé M; Castet F; Fabregat-Franco C; Escudero-Iriarte C; Escorihuela M; Arenas EJ; Bernadó-Morales C; Haro N; Giles FJ; Pozo ÓJ; Miquel JM; Nuciforo PG; Vivancos A; Melé M; Serra V; Arribas J; Tabernero J; Peiró S; Macarulla T; Tian TV
Clin Cancer Res; 2023 Jan; 29(2):432-445. PubMed ID: 36374558
[TBL] [Abstract][Full Text] [Related]
4. JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.
Garcia PL; Miller AL; Gamblin TL; Council LN; Christein JD; Arnoletti JP; Heslin MJ; Reddy S; Richardson JH; Cui X; van Waardenburg RCAM; Bradner JE; Yang ES; Yoon KJ
Mol Cancer Ther; 2018 Jan; 17(1):107-118. PubMed ID: 29142067
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
7. Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens.
Hernandez MC; Bergquist JR; Leiting JL; Ivanics T; Yang L; Smoot RL; Nagorney DM; Truty MJ
J Gastrointest Surg; 2019 Apr; 23(4):818-824. PubMed ID: 30756315
[TBL] [Abstract][Full Text] [Related]
8. Animal models of cholangiocarcinoma.
Loeuillard E; Fischbach SR; Gores GJ; Ilyas SI
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):982-992. PubMed ID: 29627364
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
[TBL] [Abstract][Full Text] [Related]
10. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
[TBL] [Abstract][Full Text] [Related]
11. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
Wu T; Jiang X; Xu B; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1448-1456. PubMed ID: 33118510
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
[TBL] [Abstract][Full Text] [Related]
13. A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
Xu Y; Leng K; Yao Y; Kang P; Liao G; Han Y; Shi G; Ji D; Huang P; Zheng W; Li Z; Li J; Huang L; Yu L; Zhou Y; Jiang X; Wang H; Li C; Su Z; Tai S; Zhong X; Wang Z; Cui Y
Hepatology; 2021 Apr; 73(4):1419-1435. PubMed ID: 32750152
[TBL] [Abstract][Full Text] [Related]
14. The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
Xu L; Wang L; Zhou L; Dorfman RG; Pan Y; Tang D; Wang Y; Yin Y; Jiang C; Zou X; Wu J; Zhang M
Neoplasia; 2019 May; 21(5):429-441. PubMed ID: 30933885
[TBL] [Abstract][Full Text] [Related]
15. Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma.
Mwesige B; Lee MR; Lee YS; Han NY; Im JE; Kim JK; Choi SI; Hong EK; Jeon AR; Park SJ; Woo SM; Kim YH
Anticancer Res; 2022 Jan; 42(1):599-608. PubMed ID: 34969769
[TBL] [Abstract][Full Text] [Related]
16. Development and Expansion of Patient-Derived Xenografts for Endometrial Cancer.
Sengal AT; Pollock PM
Methods Mol Biol; 2024; 2806():101-115. PubMed ID: 38676799
[TBL] [Abstract][Full Text] [Related]
17. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
18. Modeling of Patient-Derived Xenografts in Colorectal Cancer.
Katsiampoura A; Raghav K; Jiang ZQ; Menter DG; Varkaris A; Morelli MP; Manuel S; Wu J; Sorokin AV; Rizi BS; Bristow C; Tian F; Airhart S; Cheng M; Broom BM; Morris J; Overman MJ; Powis G; Kopetz S
Mol Cancer Ther; 2017 Jul; 16(7):1435-1442. PubMed ID: 28468778
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?
Mohr R; Özdirik B; Knorr J; Wree A; Demir M; Tacke F; Roderburg C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679791
[TBL] [Abstract][Full Text] [Related]
20. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
